Phase II study of CHIP chemotherapy in advanced adenocarcinomas of the upper gastrointestinal tract Journal Article
| Authors: | Goldenberg, A. S.; Kelsen, D.; Dougherty, J.; Magill, G. |
| Article Title: | Phase II study of CHIP chemotherapy in advanced adenocarcinomas of the upper gastrointestinal tract |
| Abstract: | Iproplatin (CHIP) is a second generation cisplatin analogue which has completed its Phase I trials. We studied the efficacy and toxicity of CHIP in 36 previously untreated patients with advanced upper gastrointestinal tract adenocarcinomas (GE junction, cardia, antrum and body of the stomach). The starting dose was 275 mg/m2; course were repeated on an every four week schedule. Thirty-five patients were evaluable for response. Three partial remissions (8.5%) [95% confidence limits 2.5-15%] were seen. Toxicity was tolerable and included mild myelosuppression and mild nausea and vomiting. Although well tolerated, in patients with gastric and GE junction adenocarcinomas, CHIP chemotherapy was not more and probably slightly less, effective than the parent analogue cisplatin. © 1990 Kluwer Academic Publishers. |
| Keywords: | adult; cancer chemotherapy; clinical article; aged; aged, 80 and over; advanced cancer; antineoplastic agents; adenocarcinoma; phase 2 clinical trial; bone marrow suppression; nausea; vomiting; gastrointestinal neoplasms; remission induction; stomach adenocarcinoma; organoplatinum compounds; intravenous drug administration; middle age; drug evaluation; human; male; female; priority journal; article; iproplatin; gastric cancer chip |
| Journal Title: | Investigational New Drugs |
| Volume: | 8 |
| Issue: | 1 |
| ISSN: | 0167-6997 |
| Publisher: | Springer |
| Date Published: | 1990-02-01 |
| Start Page: | 71 |
| End Page: | 75 |
| Language: | English |
| DOI: | 10.1007/bf00216927 |
| PUBMED: | 2345073 |
| PROVIDER: | scopus |
| DOI/URL: | |
| Notes: | Source: Scopus |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work